Compare HP Inc (HPQ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Neurocrine Biosciences Inc — how do they compare? HP Inc trades at $30.2 (market cap $29.25B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: HP Inc is far larger — about 2× Neurocrine Biosciences Inc's market cap, and HP Inc pays a 3.7% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HPQ | NBIX | |
|---|---|---|
Market Cap | $29.25B | $14.36B |
Volume | 10,025,806 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $35.48 | $185.50 |
52-Week Low | $18.20 | $123.10 |
Typical Hold Time | 69 Days | 23 Days |
Enterprise Value | $35.42B | $14.37B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.44, up 0.62% today, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue is projected to grow to $59.2B in 2026, though net margins are compressing. Recent news highlights HP's new AI-ready PCs but also a cautious outlook for 2027 PC sales.
The outlook is mixed: valuation appears reasonable with a P/E of 12.38, but declining PC demand poses a headwind. Analyst consensus is cautious with a hold-heavy rating, though the stock offers a 3.82% dividend yield. Key risks include execution in a competitive hardware market and macroeconomic sensitivity.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
